Aspergillus species and other molds in respiratory samples from patients with cystic fibrosis: A laboratory-based study with focus on Aspergillus fumigatus azole resistance

Journal of Clinical Microbiology

Volumn 49, Issue 6, 2011, Pages 2243-2251

  Mortensen, Klaus Leth ^a   Jensen, Rasmus Hare ^a   Johansen, Helle Krogh ^b   Skov, Marianne ^b   Pressler, Tacjana ^b   Howard, Susan Julie ^c   Leatherbarrow, Howard ^c   Mellado, Emilia ^d   Arendrup, Maiken Cavling ^a  

^a STATENS SERUM INSTITUT   (Denmark)

^b Rigshospitalet   (Denmark)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ARTICLE; ASPERGILLUS FUMIGATUS; CONTROLLED STUDY; CYSTIC FIBROSIS; FUNGAL COLONIZATION; FUNGAL STRAIN; FUNGUS ISOLATION; GENE SEQUENCE; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MOLECULAR DYNAMICS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTIFUNGAL AGENTS; ASPERGILLUS FUMIGATUS; AZOLES; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG RESISTANCE, FUNGAL; FEMALE; FUNGAL PROTEINS; FUNGI; GENOTYPE; HUMANS; INFANT; LUNG DISEASES, FUNGAL; MALE; MICROBIAL SENSITIVITY TESTS; MICROSATELLITE REPEATS; MIDDLE AGED; MUTATION, MISSENSE; MYCOLOGICAL TYPING TECHNIQUES; PREVALENCE; YOUNG ADULT;

ASPERGILLUS; ASPERGILLUS FUMIGATUS; BACTERIA (MICROORGANISMS);

EID: 79957438194     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00213-11     Document Type: Article

References (54)

1. Alcazar-Fuoli, L., E. Mellado, A. Alastruey-Izquierdo, M. Cuenca-Estrella, and J. L. Rodriguez-Tudela. 2008. Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification. Antimicrob. Agents Chemother. 52:1244-1251.
2. Amin, R., A. Dupuis, S. D. Aaron, and F. Ratjen. 2010. The effect of chronic infection with Aspergillus fumigatus on lung function and hospitalization in patients with cystic fibrosis. Chest 137:171-176.
3. Amorim, A., L. Guedes-Vaz, and R. Araujo. 2010. Susceptibility to five antifungals of Aspergillus fumigatus strains isolated from chronically colonised cystic fibrosis patients receiving azole therapy. Int. J. Antimicrob. Agents 35:396-399.
4. Bakare, N., V. Rickerts, J. Bargon, and G. Just-Nubling. 2003. Prevalence of Aspergillus fumigatus and other fungal species in the sputum of adult patients with cystic fibrosis. Mycoses 46:19-23. (Pubitemid 36278895)
5. Balajee, S. A., J. L. Gribskov, E. Hanley, D. Nickle, and K. A. Marr. 2005. Aspergillus lentulus sp. nov., a new sibling species of A. fumigatus. Eukaryot. Cell 4:625-632.
6. Barton, R. C., et al. 2010. Isolation of the fungus Geosmithia argillacea in the sputum of people with cystic fibrosis. J. Clin. Microbiol. 48:2615-2617.
7. Bauernfeind, A., et al. 1987. Qualitative and quantitative microbiological analysis of sputa of 102 patients with cystic fibrosis. Infection 15:270-277.
8. Borman, A. M., et al. 2010. Lack of standardization in the procedures for mycological examination of sputum samples from CF patients: a possible cause for variations in the prevalence of filamentous fungi. Med. Mycol. 48:S88-S97.
9. Bouchara, J. P., et al. 2009. Development of an oligonucleotide array for direct detection of fungi in sputum samples from patients with cystic fibrosis. J. Clin. Microbiol. 47:142-152.
10. Brillowska-Dabrowska, A., D. M. Saunte, and M. C. Arendrup. 2007. Fivehour diagnosis of dermatophyte nail infections with specific detection of Trichophyton rubrum. J. Clin. Microbiol. 45:1200-1204.
11. Bueid, A., et al. 2010. Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009. J. Antimicrob. Chemother. 65:2116-2118.
12. Burns, J. L., et al. 1998. Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin. Infect. Dis. 27:158-163.
13. Cimon, B., et al. 2000. Clinical significance of Scedosporium apiospermum in patients with cystic fibrosis. Eur. J. Clin. Microbiol. Infect. Dis. 19:53-56.
14. Cimon, B., et al. 2005. Airway colonization by Acrophialophora fusispora in patients with cystic fibrosis. J. Clin. Microbiol. 43:1484-1487.
15. Cimon, B., et al. 2001. Molecular epidemiology of airway colonisation by Aspergillus fumigatus in cystic fibrosis patients. J. Med. Microbiol. 50:367-374.
16. Cornely, O. A., et al. 2007. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med. 356:348-359.
17. de Almeida, M. B., M. H. Bussamra, and J. C. Rodrigues. 2006. Allergic bronchopulmonary aspergillosis in paediatric cystic fibrosis patients. Paediatr. Respir. Rev. 7:67-72.
18. de Hoog, G. S., J. Guarro, J. Gene, and M. J. Figueras. 2001. Atlas of clinical fungi. ASM Press, Washington, DC.
19. Denning, D. W., et al. 1997. Itraconazole resistance in Aspergillus fumigatus. Antimicrob. Agents Chemother. 41:1364-1368.
20. de Valk, H. A., et al. 2009. Molecular typing and colonization patterns of Aspergillus fumigatus in patients with cystic fibrosis. J. Cyst. Fibros. 8:110-114.
21. de Valk, H. A., et al. 2005. Use of a novel panel of nine short tandem repeats for exact and high-resolution fingerprinting of Aspergillus fumigatus isolates. J. Clin. Microbiol. 43:4112-4120.
22. De Vrankrijker, A. M., et al. 2010. Aspergillus fumigatus colonisation in cystic fibrosis: implications for lung function? Clin. Microbiol. Infect. [Epub ahead of print.] doi:10.1111/j.1469-0691.2010.03429.x.
23. Henry, T., P. C. Iwen, and S. H. Hinrichs. 2000. Identification of Aspergillus species using internal transcribed spacer regions 1 and 2. J. Clin. Microbiol. 38:1510-1515.
24. Herbrecht, R., et al. 2002. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347:408-415.
25. Horre, R., et al. 2004. Isolation of fungi, especially Exophiala dermatitidis, in patients suffering from cystic fibrosis. A prospective study. Respiration 71:360-366. (Pubitemid 39179171)
26. Howard, S. J., and M. C. Arendrup. 2011. Acquired antifungal drug resistance in Aspergillus fumigatus: epidemiology and detection. Med. Mycol. 49:S90-S95.
27. Howard, S. J., et al. 2009. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg. Infect. Dis. 15:1068-1076.
28. Howard, S. J., A. C. Pasqualotto, and D. W. Denning. 2010. Azole resistance in allergic bronchopulmonary aspergillosis and Aspergillus bronchitis. Clin. Microbiol. Infect. 16:683-688.
29. Kraemer, R., N. Delosea, P. Ballinari, S. Gallati, and R. Crameri. 2006. Effect of allergic bronchopulmonary aspergillosis on lung function in children with cystic fibrosis. Am. J. Respir. Crit. Care Med. 174:1211-1220.
30. Lagrou, K., et al. 2008. Triazole resistance among clinical Aspergillus fumigatus isolates, abstr. P-33. 3rd Adv. Aspergillosis Meet., 16 to 19 January 2008, Miami, FL.
31. Leon, E. E., and T. J. Craig. 1999. Antifungals in the treatment of allergic bronchopulmonary aspergillosis. Ann. Allergy Asthma Immunol. 82:511-516.
32. Lipuma, J. J. 2010. The changing microbial epidemiology in cystic fibrosis. Clin. Microbiol. Rev. 23:299-323.
33. Massam, J., et al. 2011. Invasive aspergillosis in cystic fibrosis: a fatal case in an adolescent and review of the literature. Pediatr. Infect. Dis. J. 30:178-180.
34. Mellado, E., T. M. Diaz-Guerra, M. Cuenca-Estrella, and J. L. Rodriguez-Tudela. 2001. Identification of two different 14-alpha sterol demethylase-related genes (cyp51A and cyp51B) in Aspergillus fumigatus and other Aspergillus species. J. Clin. Microbiol. 39:2431-2438.
35. Milla, C. E., C. L. Wielinski, and W. E. Regelmann. 1996. Clinical significance of the recovery of Aspergillus species from the respiratory secretions of cystic fibrosis patients. Pediatr. Pulmonol. 21:6-10.
36. Mortensen, K. L., et al. 2010. Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain. Antimicrob. Agents Chemother. 54:4545-4549.
37. Mroueh, S., and A. Spock. 1994. Allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. Chest 105:32-36. (Pubitemid 24029072)
38. Nagano, Y., et al. 2010. Comparison of techniques to examine the diversity of fungi in adult patients with cystic fibrosis. Med. Mycol. 48:166-176.
39. Nelson, L. A., M. L. Callerame, and R. H. Schwartz. 1979. Aspergillosis and atopy in cystic fibrosis. Am. Rev. Respir. Dis. 120:863-873.
40. Paugam, A., et al. 2010. Characteristics and consequences of airway colonization by filamentous fungi in 201 adult patients with cystic fibrosis in France. Med. Mycol. 48:S32-S36.
41. Pfaller, M. A., et al. 2008. In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species. J. Clin. Microbiol. 46:2568-2572.
42. Pihet, M., et al. 2009. Occurrence and relevance of filamentous fungi in respiratory secretions of patients with cystic fibrosis - a review. Med. Mycol. 47:387-397.
43. Rodriguez-Tudela, J. L., et al. 2008. Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus. Antimicrob. Agents Chemother. 52:2468-2472.
44. Rodriguez-Tudela, J. L., et al. 2008. EUCAST Technical Note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds. Clin. Microbiol. Infect. 14:982-984.
45. Schønheyder, H., T. Jensen, N. Hoiby, P. Andersen, and C. Koch. 1985. Frequency of Aspergillus fumigatus isolates and antibodies to Aspergillus antigens in cystic fibrosis. Acta Pathol. Microbiol. Immunol. Scand. B. 93:105-112.
46. Shoseyov, D., K. G. Brownlee, S. P. Conway, and E. Kerem. 2006. Aspergillus bronchitis in cystic fibrosis. Chest 130:222-226. (Pubitemid 44116864)
47. Snelders, E., et al. 2009. Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles. Appl. Environ. Microbiol. 75:4053-4057.
48. Snelders, E., et al. 2008. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med. 5:e219.
49. Stevens, D. A., et al. 2003. Allergic bronchopulmonary aspergillosis in cystic fibrosis - state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin. Infect. Dis. 37(Suppl. 3):S225-S264.
50. Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST). 2008. EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin. Microbiol. Infect. 14:398-405.
51. Vanhee, L. M., F. Symoens, J. P. Bouchara, H. J. Nelis, and T. Coenye. 2008. High-resolution genotyping of Aspergillus fumigatus isolates recovered from chronically colonised patients with cystic fibrosis. Eur. J. Clin. Microbiol. Infect. Dis. 27:1005-1007.
52. Verweij, P. E., S. J. Howard, W. J. Melchers, and D. W. Denning. 2009. Azole-resistance in Aspergillus: proposed nomenclature and breakpoints. Drug Resist. Updat. 12:141-147.
53. Verweij, P. E., E. Snelders, G. H. Kema, E. Mellado, and W. J. Melchers. 2009. Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? Lancet Infect. Dis. 9:789-795.
54. Verweij, P. E., et al. 2010. A new resistance machanism from environmental origin conferring voriconazole resistance has emerged in clinical Aspergillus fumigatus isolates in the Netherlands. 50th Intersci. Conf. Antimicrob. Agents Chemother., abstr. M-624.